Affordable access to life extending drug for people with incurable breast cancer. – Breast Cancer Network Australia
Recce Awarded AusIndustry Advanced Overseas (R&D) Finding for up to A$85m for Synthetic Anti-Infective Development Program
Lumenis Aesthetics ANZ Launches New Stellar M22(TM) XPL – A Multi-Application Platform with XPL(TM) Technology Backed by New Clinical Data
Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
Orthocell submits regulatory application for commercial distribution of Remplir into the US$750 million EU + UK nerve repair market
Pfizer and BioNTech’s LP.8.1-adapted COVID-19 vaccine now registered on the Australian Register of Therapeutic Goods
Launch of Evinco Therapeutics: A pioneering biotech company advancing immune therapies for Alzheimer’s disease – Evinco Therapeutics Pty Ltd
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
Imugene: Overall response rate increases to 82% with additional partial response in azer-cel CAR T relapsed phase 1b trial
Vertex Receives TGA Approval for ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class CFTR Modulator for the Treatment of Cystic Fibrosis
Emyria Accelerates National Expansion Following Institutional Placement. Exercises Option to Establish Victorian Empax Clinic
Emyria Accelerates National Expansion Following Institutional Placement. Exercises Option to Establish Victorian Empax Clinic
Australian government Takeovers Panel: Mayne Pharma Group Limited – Declaration of Unacceptable Circumstances and Orders